Comparative Pharmacology
Head-to-head clinical analysis: ETHMOZINE versus PRONESTYL SR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHMOZINE versus PRONESTYL SR.
ETHMOZINE vs PRONESTYL-SR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
Class Ia antiarrhythmic agent; blocks sodium channels, slowing phase 0 depolarization and decreasing myocardial excitability; also prolongs refractory period and has anticholinergic effects.
200-300 mg orally every 8 hours; maximum 900 mg/day.
500–1000 mg orally every 6 hours (sustained-release). Maximum 1.5 g per dose or 4 g per day.
None Documented
None Documented
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
2.5-4.7 hours (procainamide); 6-9 hours (NAPA, active metabolite). Prolonged in renal impairment (up to 11-20 hours for procainamide, 30-42 hours for NAPA).
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Renal excretion: ~50-60% unchanged drug (procainamide), ~15-30% as N-acetylprocainamide (NAPA). Biliary/fecal: minor (<5%).
Category C
Category C
Antiarrhythmic
Antiarrhythmic